Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1:14:1587-1595.
doi: 10.2147/IJN.S195048. eCollection 2019.

Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats

Md Khalid Anwer  1 , Muqtader Mohammad  1 , Essam Ezzeldin  2   3 , Farhat Fatima  1 , Ahmed Alalaiwe  1 , Muzaffar Iqbal  2   3
Affiliations

Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats

Md Khalid Anwer et al. Int J Nanomedicine. .

Abstract

Background: Apremilast (APM) is a novel, orally administered small molecule drug approved for treatment of psoriasis or psoriatic arthritis. Due to its low solubility and permeability, it is classified as a class IV drug according to BCS classification. Dose titration is recommended during APM treatment due to its tolerability and twice-daily dosing regimen issues.

Materials and methods: In this study, three different APM-loaded PLGA nanoparticles (F1-F3) were prepared by single emulsion and evaporation method. Based on particle size, PDI, zeta potential (ZP), entrapment efficiency (%EE), drug loading (%DL), and spectral characterization, the nanoparticles (F3) were optimized. The F3 nanoparticles were further evaluated for in vitro release and in vivo pharmacokinetic studies in rats.

Results: The optimized nanoparticles (F3) had particles size 307.3±8.5 nm with a low PDI value 0.317, ZP of -43.4±2.6 mV, EE of 61.1±1.9% and DL of 1.9±0.1%. The in vitro release profile showed a sustained release pattern of F3 nanoparticles of APM. The pharmacokinetic results showed 2.25 times increase in bio-availability of F3 nanoparticles compared to normal APM suspension. Moreover, significant increase in half-life and mean residence time confirms long-term retention of F3 nanoparticles.

Conclusion: Bioavailability enhancement along-with long-term retention of the APM-loaded PLGA nanoparticles might be helpful for the once-daily regimen treatment.

Keywords: Poly(D,L-lactide-coglycolide); apremilast; bioavailability; nanoparticles; sustained release.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
FTIR spectra of APM and APM-loaded PLGA NPs (F1–F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nano-particles.
Figure 2
Figure 2
DSC thermogram of APM and APM-loaded PLGA NPs (F1–F3). Abbreviations: APM, apremilast; DSC, differential scanning calorimetry; PLGA NPs, poly(D,L-lactide-coglycolide) nanoparticles.
Figure 3
Figure 3
Powder X-ray diffraction pattern of APM and APM-loaded PLGA NPs (F1–F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nanoparticles.
Figure 4
Figure 4
SEM images of optimized APM-loaded PLGA NPs (F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nanoparticles.
Figure 5
Figure 5
Release profile of pure APM and APM-loaded PLGA NPs (F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nano-particles.
Figure 6
Figure 6
Higuchi release kinetics APM-loaded PLGA NPs (F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nanoparticles.
Figure 7
Figure 7
Pharmacokinetic profile of pure APM suspension and APM-loaded PLGA NPs (F3). Abbreviations: APM, apremilast; PLGA NPs, poly(D,L-lactide-coglycolide) nanoparticles.
Figure 8
Figure 8
Representative MRM chromatogram of APM and IS in actual plasma sample at 1 hour after oral administration of APM (2 mg/kg). Abbreviations: APM, apremilast; IS, internal standard; MRM, multiple reaction monitoring.
See this image and copyright information in PMC

References

    1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. - PubMed
    1. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–864. - PubMed
    1. Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75(12):1393–1403. - PubMed
    1. Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13(10):1461–1473. - PubMed
    1. Assessment report of Apremilast (Otezla) Committee for medicinal products for human use. European Medicines Agency. 2014

MeSH terms